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Chronic myeloproliferative neoplasms (MPN) are a group of blood malignances 
that originate from the transformation of a pluripotent stem cell, and are characterized 
by clonal proliferation of one or more hematopoietic progenitors in the bone marrow 
and extramedullary sites. The biological definition of such diseases is historically rep-
resented by the absence of the Philadelphia chromosome (crPh-), and the fusion gene 
BCR / ABL known by the t (9; 22), which characterizes chronic myeloid leukemia 
(CML) (crPh +) (Barosi G et al. 2008; Vannucchi AM et al., 2008). 
The three main myeloproliferative disorders (crPh-) are the Polycythemia Vera, 
Essential Thrombocythemia and Primary Myelofibrosis. However, the World Health 
Organization (WHO) includes among the myeloproliferative neoplasms also less fre-
quent diseases: systemic mastocytosis, chronic eosinophilic leukemia, chronic neu-
trophilic leukemia, and chronic myelomonocytic leukemia. The annual incidence of 
MPN is 1 to 3 cases per 100,000 / inhabitants for PV and ET, while the IMF is more 
rare. 
Primary Myelofibrosis (PMF) is a chronic and malignant neoplasm, characterized 
by splenomegaly, presence of circulating hematopoietic progenitors and an-
isopoichilocitosis with dacryocytes, a different stages of marrow fibrosis and extrame-
dullary hematopoiesis. It is a rare disease, with an incidence of 0.5-1.5 cases per 
100,000 inhabitants per year and affects both sexes equally; the average age at diag-
nosis is 60 years. Approximately 20% of patients are completely asymptomatic at 
diagnosis, but when symptoms are present they are related to the stages of anemia or 
splenomegaly (Cervantes F et al., 1997). The terms primary and idiopathic mean that 
in these cases the disease is of unknown or spontaneous origin. This is in contrast with 
myelofibrosis that develops secondary to polycythemia vera or essential thrombo-
cythaemia (secondary myelofibrosis).  
The reticolinic fibrosis is an exaggeration of normal pattern of fibers in the me-
dulla, and is comprised of collagen type I and III and fibronectin. The fibrous colla-
gen, however, is responsible for the disruption of the bone marrow architecture and is 
present in both primary and secondary myelofibrosis. In Idiopathic Myelofibrosis has 
been observed a steady increase in the deposition of collagen, especially in patients 
with long-term illness. The increase of these proteins is observed also in the serum, 
especially of patients with active disease. The marrow fibrosis is a potentially reversi-
